BIAF · bioAffinity Technologies, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company's current expected level of operating expenditures and the cash and cash equivalents on hand at June 30, 2026, management concludes that there is substantial doubt about the Company's ability to continue as a going concern for a period of at least twelve (12) months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 7, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $5.9M | $6.16M | $9.36M | $7.9M | $6.9M | — | |
| — | — | — | — | $467 | — | |
| — | — | — | — | $4336 | — | |
| — | — | — | — | 0.06% | — | |
| $1.42M | $1.38M | $1.46M | $1.47M | $1.38M | $1.01M | |
| $11.35M | $9.91M | $9.94M | $6.79M | $2.48M | $1.07M | |
| $58.33K | $58.33K | $58.33K | $16.53K | $0 | — | |
| $413.09K | $504.84K | $605.64K | $249.59K | $10.18K | $4817 | |
| $18.28M | $16.73M | $18.32M | $10.51M | $4.02M | $2.21M | |
| -$12.38M | -$10.57M | -$8.95M | -$7.97M | -$4.01M | -$2.21M | |
| — | -171.58% | -95.64% | -100.93% | -58.13% | — | |
| -$11.97M | -$10.07M | -$8.35M | -$7.72M | -$4M | -$2.2M | |
| $44.84K | $44.37K | $92.48K | $37.13K | $2.53M | $1M | |
| $34.2K | $23.39K | $17.61K | $122.13K | $46.71K | $424 | |
| -$2.8M | -$4.29M | -$74.74K | $57.21K | -$4.14M | — | |
| -$15.18M | -$14.87M | -$9.03M | -$7.92M | -$8.15M | -$6.32M | |
| — | $44.04K | $11.65K | $20.99K | $2459 | $1950 | |
| -$15.19M | -$14.91M | -$9.04M | -$7.94M | -$8.15M | -$6.33M | |
| — | -241.96% | -96.56% | -100.47% | -118.18% | — | |
| USD/shares | — | -$8.66 | -$22.50 | -$27.30 | -$54.30 | -$70.80 |
| USD/shares | — | -$8.66 | -$22.50 | -$27.30 | -$54.30 | — |
| shares | — | 1.72M | 404.17K | 291.58K | 149.97K | 89.18K |
| shares | — | 1.72M | 404.17K | 291.58K | 149.97K | — |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 10 similar-size Diagnostics & Research companies (of 49 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Laboratory Services | $6,161,382 | $9,353,368 | $2,513,057 | $4,803 |
| Health Care Patient Service | $4,971,342 | $8,175,670 | $2,199,558 | — |
| Histology Service Fees | $1,116,912 | $1,103,751 | $272,660 | — |
| Medical Director Fees | $68,268 | $66,576 | $19,324 | — |
| Other Revenues | $4,860 | $7,371 | $21,515 | — |
| Department of Defense Observational Studies | $577 | $8,654 | $19,442 | — |
| Diagnostic Research and Development | $577 | $8,654 | $19,442 | — |
| Department of Defense Observational Studiesr | — | — | $19,442 | — |
| Histology Fees | — | — | $272,660 | — |
| Health Care Other | — | — | $19,324 | — |